State Street SPDR S&P Pharmaceuticals ETF XPH
64.75 USD +2.10 (+3.35%)
At closeNov 6, 2026, 5:05 PM EST
64.75 0.00 0.00%
After hours · Nov 6, 5:05 PM ET
62.99 Day range 65.05
48.30 52-week range 74.06
- YTD
- +15.60%
- 1 year
- +33.26%
- Market cap
- 252.66M
- EPS (ttm)
- 3.87
- P/E ratio
- 16.72
- YTD return
- +15.60%
- 1-year return
- +33.26%
- Volume
- 171.09K
- Avg volume
- 190.77K
- Open
- 62.97
- Previous close
- 62.65
- Day's range
- 62.99 – 65.05
- 52-week range
- 48.30 – 74.06
1Y +16.53 (+34.22%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 45.94
- 200-day average
- 42.92
About State Street SPDR S&P Pharmaceuticals ETF
In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").
News
Two Years to Build or Pay 200% — Which US Pharma Stocks Win? 
Why Is Organon Stock Skyrocketing Monday? 
Why Is Amneal Pharmaceuticals Stock Gaining Today? 
Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda 
Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks' 
Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts 
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' 
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms 
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing 
Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More'
Your note
Sign in to keep a note on XPH — it syncs with the Stock Master app.